Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HZBio2
- Development stage
- Phase 3
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HZBio2 is a biosimilar candidate of vedolizumab, a humanized monoclonal antibody. It is developed by Hangzhou Yuanda Biopharmaceutical for the treatment of inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Like the reference product, HZBio2 binds to the human α4β7 integrin, a glycoprotein expressed on the surface of a subset of gastrointestinal-homing T lymphocytes. By blocking the interaction of α4β7 with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), it inhibits the migration of these inflammatory cells into the gastrointestinal mucosa, thereby reducing inflammation.
- Other names
- vedolizumab biosimilar
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)
Beyond the preview
Go deeper on HZBio2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HZBio2.